A Tundo1, R de Filippis1, F De Crescenzo2,3,4. 1. Istituto di Psicopatologia, Rome, Italy. 2. Department of Psychiatry, University of Oxford, Oxford, UK. 3. Department (DPUO), Pediatric University Hospital, Bambino Gesù Children's Hospital, Rome, Italy. 4. Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.
Abstract
OBJECTIVE: Several depressed patients do not respond to traditional antidepressants. Our aim was to systematically review the effectiveness and safety of pramipexole in unipolar and bipolar depression. METHODS: We conducted a systematic review of randomized clinical trials (RCTs) and observational studies on pramipexole for patients with major depressive episodes, following PRISMA guidelines. Our primary outcome measure was treatment response at endpoint. The study protocol was registered on PROSPERO: CRD42018108699. RESULTS: We found five RCTs, three open-label trials and five observational studies, with 504 participants (57% women; mean age, 45.3 years; mean sample size, 39; median duration of treatment, 8 weeks; mean follow-up duration, 45 weeks; mean maximum dose, 1.62 mg). We found an overall short-term response rate of 52.2% and remission rate of 36.1%, and an overall long-term response rate of 62.1% and remission rate of 39.6%. In RCTs, patients treated with pramipexole had a superior response rate compared with placebo (RR: 1.77; 95% CI: 1.11-2.82) and similar to SSRIs (RR: 0.93; 95% CI: 0.44-1.95). Acceptability and tolerability were good, with nausea being the most frequent side-effect. CONCLUSION: Our study found some evidence for an effect of pramipexole for the treatment of major depressive episodes.
OBJECTIVE: Several depressed patients do not respond to traditional antidepressants. Our aim was to systematically review the effectiveness and safety of pramipexole in unipolar and bipolar depression. METHODS: We conducted a systematic review of randomized clinical trials (RCTs) and observational studies on pramipexole for patients with major depressive episodes, following PRISMA guidelines. Our primary outcome measure was treatment response at endpoint. The study protocol was registered on PROSPERO: CRD42018108699. RESULTS: We found five RCTs, three open-label trials and five observational studies, with 504 participants (57% women; mean age, 45.3 years; mean sample size, 39; median duration of treatment, 8 weeks; mean follow-up duration, 45 weeks; mean maximum dose, 1.62 mg). We found an overall short-term response rate of 52.2% and remission rate of 36.1%, and an overall long-term response rate of 62.1% and remission rate of 39.6%. In RCTs, patients treated with pramipexole had a superior response rate compared with placebo (RR: 1.77; 95% CI: 1.11-2.82) and similar to SSRIs (RR: 0.93; 95% CI: 0.44-1.95). Acceptability and tolerability were good, with nausea being the most frequent side-effect. CONCLUSION: Our study found some evidence for an effect of pramipexole for the treatment of major depressive episodes.
Authors: Ivan Aprahamian; Marcus K Borges; Denise J C Hanssen; Hans W Jeuring; Richard C Oude Voshaar Journal: Clin Interv Aging Date: 2022-06-22 Impact factor: 3.829
Authors: Sheena Kristine Au-Yeung; James Griffiths; Sophie Roberts; Chloe Edwards; Ly-Mee Yu; Rafal Bogacz; Jennifer Rendell; Mary-Jane Attenburrow; Stuart Watson; Fiona Chan; Andrea Cipriani; Anthony Cleare; Catherine J Harmer; David Kessler; Jonathan Evans; Glyn Lewis; Ilina Singh; Judit Simon; Paul J Harrison; Phil Cowen; Milensu Shanyinde; John Geddes; Michael Browning Journal: Evid Based Ment Health Date: 2021-11-22
Authors: Alexander Kaltenboeck; Don Chamith Halahakoon; Catherine J Harmer; Philip Cowen; Michael Browning Journal: Int J Neuropsychopharmacol Date: 2022-09-28 Impact factor: 5.678
Authors: Filip Ventorp; Jesper Lindahl; Danielle van Westen; Jimmy Jensen; Johannes Björkstrand; Daniel Lindqvist Journal: Psychiatr Res Clin Pract Date: 2022-04-30